SNDL INC (SNDL) Stock Fundamental Analysis
USA - NASDAQ:SNDL - CA83307B1013 - Common Stock
1.68 USD
-0.02 (-1.18%)
1.6807 USD
+0 (+0.04%)
Overall SNDL gets a fundamental rating of 3 out of 10. We evaluated SNDL against 192 industry peers in the Pharmaceuticals industry. While SNDL seems to be doing ok healthwise, there are quite some concerns on its profitability. SNDL does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
SNDL had negative earnings in the past year.
SNDL had a positive operating cash flow in the past year.
SNDL had negative earnings in each of the past 5 years.
In the past 5 years SNDL reported 4 times negative operating cash flow.
1.2 Ratios
SNDL has a better Return On Assets (-7.60%) than 70.83% of its industry peers.
With a decent Return On Equity value of -9.03%, SNDL is doing good in the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROIC | N/A |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
SNDL has a Gross Margin of 27.11%. This is comparable to the rest of the industry: SNDL outperforms 54.69% of its industry peers.
In the last couple of years the Gross Margin of SNDL has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for SNDL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
SNDL does not have a ROIC to compare to the WACC, probably because it is not profitable.
SNDL has about the same amout of shares outstanding than it did 1 year ago.
SNDL has more shares outstanding than it did 5 years ago.
SNDL has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of 1.38, we must say that SNDL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.38, SNDL is in the better half of the industry, outperforming 60.94% of the companies in the same industry.
The Debt to FCF ratio of SNDL is 3.03, which is a good value as it means it would take SNDL, 3.03 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.03, SNDL belongs to the top of the industry, outperforming 90.10% of the companies in the same industry.
SNDL has a Debt/Equity ratio of 0.11. This is a healthy value indicating a solid balance between debt and equity.
SNDL has a Debt to Equity ratio of 0.11. This is comparable to the rest of the industry: SNDL outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.38 |
ROIC/WACCN/A
WACC7.85%
2.3 Liquidity
A Current Ratio of 5.03 indicates that SNDL has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 5.03, SNDL is in the better half of the industry, outperforming 68.23% of the companies in the same industry.
SNDL has a Quick Ratio of 3.36. This indicates that SNDL is financially healthy and has no problem in meeting its short term obligations.
SNDL has a Quick ratio (3.36) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 |
3. Growth
3.1 Past
SNDL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 85.64%, which is quite impressive.
SNDL shows a decrease in Revenue. In the last year, the revenue decreased by -7.88%.
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.59%
Revenue 1Y (TTM)-7.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.35%
3.2 Future
The Earnings Per Share is expected to grow by 14.96% on average over the next years. This is quite good.
SNDL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.19% yearly.
EPS Next Y40.31%
EPS Next 2Y33.31%
EPS Next 3Y23.32%
EPS Next 5Y14.96%
Revenue Next Year1181.89%
Revenue Next 2Y311.6%
Revenue Next 3Y157.37%
Revenue Next 5Y79.19%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
SNDL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SNDL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, SNDL is valued cheaper than 83.85% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, SNDL is valued cheaper than 88.54% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.19 | ||
| EV/EBITDA | 12.03 |
4.3 Compensation for Growth
SNDL's earnings are expected to grow with 23.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y33.31%
EPS Next 3Y23.32%
5. Dividend
5.1 Amount
No dividends for SNDL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
1.68
-0.02 (-1.18%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners16.56%
Inst Owner Change33.86%
Ins Owners4.32%
Ins Owner ChangeN/A
Market Cap432.35M
Revenue(TTM)56.10M
Net Income(TTM)-98.29M
Analysts82.5
Price Target5.71 (239.88%)
Short Float %0.8%
Short Ratio0.51
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.42%
Min EPS beat(2)63.24%
Max EPS beat(2)119.61%
EPS beat(4)3
Avg EPS beat(4)122.67%
Min EPS beat(4)-37.25%
Max EPS beat(4)345.1%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.36%
Min Revenue beat(2)-6.38%
Max Revenue beat(2)3.66%
Revenue beat(4)2
Avg Revenue beat(4)-0.24%
Min Revenue beat(4)-6.38%
Max Revenue beat(4)3.66%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)37.8%
PT rev (3m)24.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-20%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.12%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.64 | ||
| P/FCF | 12.19 | ||
| P/OCF | 9.97 | ||
| P/B | 0.56 | ||
| P/tB | 0.67 | ||
| EV/EBITDA | 12.03 |
EPS(TTM)-0.02
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)0.14
FCFY8.2%
OCF(TTM)0.17
OCFY10.03%
SpS2.62
BVpS3.02
TBVpS2.51
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.6% | ||
| ROE | -9.03% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 27.11% | ||
| FCFM | 5.27% |
ROA(3y)-13.41%
ROA(5y)-27.04%
ROE(3y)-16.09%
ROE(5y)-30.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y38.61%
GM growth 5Y-0.23%
F-Score7
Asset Turnover0.73
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.11 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.6 | ||
| Cap/Depr | 19.75% | ||
| Cap/Sales | 1.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 135.06% | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.03 | ||
| Quick Ratio | 3.36 | ||
| Altman-Z | 1.38 |
F-Score7
WACC7.85%
ROIC/WACCN/A
Cap/Depr(3y)18.2%
Cap/Depr(5y)23.85%
Cap/Sales(3y)1.2%
Cap/Sales(5y)3.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)85.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%19.59%
EPS Next Y40.31%
EPS Next 2Y33.31%
EPS Next 3Y23.32%
EPS Next 5Y14.96%
Revenue 1Y (TTM)-7.88%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%5.35%
Revenue Next Year1181.89%
Revenue Next 2Y311.6%
Revenue Next 3Y157.37%
Revenue Next 5Y79.19%
EBIT growth 1Y76.54%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year710.87%
EBIT Next 3Y150.28%
EBIT Next 5Y93%
FCF growth 1Y268.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y397.24%
OCF growth 3YN/A
OCF growth 5YN/A
SNDL INC / SNDL FAQ
Can you provide the ChartMill fundamental rating for SNDL INC?
ChartMill assigns a fundamental rating of 3 / 10 to SNDL.
What is the valuation status for SNDL stock?
ChartMill assigns a valuation rating of 3 / 10 to SNDL INC (SNDL). This can be considered as Overvalued.
What is the profitability of SNDL stock?
SNDL INC (SNDL) has a profitability rating of 2 / 10.
What is the financial health of SNDL INC (SNDL) stock?
The financial health rating of SNDL INC (SNDL) is 6 / 10.